[NDSN] Nordson Thesis 2026: 62-Year Dividend Aristocrat Tests Industrial Cycle Recovery
Key Takeaways
- 62-Year Dividend Aristocrat:
$2.72-2.85 annual dividend FY2025 ($0.68-0.71/quarter; ~62 consecutive year continuous increases since 1956 — selected longest dividend track record on NASDAQ exchange); selected dividend aristocrat trajectory; ~5-10% annual increases; FY2026 expected dividend toward $2.90-3.10 (+5-10%); selected ~63-year dividend continuity through FY2026. - Industrial Precision Solutions Cycle: Industrial Precision Solutions revenue ~$1.4B FY2025 (~50% of total; +0-5% YoY); selected adhesive dispensing + polymer processing; selected post-2024 industrial cycle weakness affecting selected packaging + selected industrial + selected consumer non-durables; FY2026 expected IPS toward $1.45-1.55B (+3-7%) on selected industrial cycle recovery.
- April 2024 ARAG Group $960M Integration: April 1, 2024 ARAG Group $960M acquisition (precision agriculture spraying + selected); selected ~$200M+ FY2025 revenue contribution within Industrial Precision Solutions; selected ~$50-75M expected cost synergies + selected revenue cross-sell; FY2026 catalyst: continued ARAG integration completion + selected precision agriculture market expansion.
- Medical & Fluid + Advanced Tech Diversification: Medical & Fluid Solutions ~$700M FY2025 (~25% of total) selected medical device fluid components + selected post-2024 medical device cycle stability; Advanced Technology Solutions ~$700M (~25%) selected electronics dispensing + test/inspection + selected post-2024 semiconductor capex recovery; FY2026 expected continued diversification benefit.
Company Background
Nordson Corporation (NASDAQ: NDSN) is the leading global precision dispensing + adhesive systems firm focused on industrial precision dispensing technology + medical fluid components + advanced technology systems. Founded 1954 by Eric Nord as Nordson Corp in Amherst Ohio (selected ~71-year heritage; selected initial focus on industrial adhesive dispensing); IPO 1971 NASDAQ; selected various transformative acquisitions through history including selected 2010 EDI $200M + selected 2017 Vention Medical $705M + selected 2022 CyberOptics $380M + selected April 2024 ARAG Group $960M.
The company operates three reporting segments: Industrial Precision Solutions ~50% of revenue ($1.4B — selected adhesive dispensing + selected polymer processing + selected non-woven systems + selected post-2024 ARAG Group precision agriculture), Medical & Fluid Solutions ~25% ($700M — selected medical device fluid components + selected interventional + selected post-2017 Vention Medical integration), and Advanced Technology Solutions ~25% ($700M — selected electronics dispensing + selected test/inspection + selected post-2022 CyberOptics integration).
The company employs ~7,800+ globally headquartered in Westlake Ohio with FY2025 (fiscal year ending October 2026) revenue ~$2.6-2.8B (+0-5% YoY) generating ~$500-600M net income (~18-22% net margin) and ~$8.50-10.00 EPS on ~57M diluted shares.
CEO Sundaram Nagarajan since August 2019 (~6-year tenure; succeeded Michael Hilton CEO 2010-August 2019 retired who led 2010-2019 strategic transformation including selected 2017 Vention Medical $705M; Nagarajan ex-Illinois Tool Works VP/General Manager + selected ~25-year industrial career; Indian-American). CFO Joseph Kelley since 2019.
62-Year Dividend Aristocrat: Longest NASDAQ Track Record
Nordson's defining capital allocation hallmark involves ~62 consecutive year continuous dividend increases (since 1956) representing selected longest dividend track record on NASDAQ exchange + selected one of longest in S&P 500. Selected dividend $2.72-2.85/share annual FY2025 ($0.68-0.71/quarter; ~5-10% annual increases; selected dividend yield ~1.0-1.5%). FY2026 expected dividend toward $2.90-3.10 (+5-10%) maintaining ~63-year dividend continuity through FY2026.
Selected modest buybacks ~$50-200M FY2025 (selected post-ARAG deleveraging) + selected investment-grade A2/A credit ratings reflecting selected disciplined capital allocation + selected stable cash flow generation through industrial cycles.
Material change rule: dividend cut would end ~62-year continuous track record (selected one of most prestigious dividend records in S&P 500; would require severe cash flow compression OR major leverage event) OR major dividend growth deceleration below 3% YoY.
Industrial Precision Solutions: $1.4B Trajectory + ARAG Integration
Industrial Precision Solutions revenue ~$1.4B FY2025 (50% of total; +0-5% YoY) reflects: (i) selected adhesive dispensing (selected packaging + selected non-woven hygiene products + selected consumer non-durables); (ii) selected polymer processing (selected plastics extrusion + selected); (iii) selected post-2024 industrial cycle weakness affecting selected packaging + selected industrial customers; (iv) selected April 2024 ARAG Group $960M acquisition ($200M+ FY2025 revenue contribution).
April 1, 2024 ARAG Group $960M all-cash acquisition: selected precision agriculture spraying + selected agricultural electronics + selected ~$200M+ standalone revenue + selected European agricultural market exposure. Selected ~$50-75M expected cost synergies + selected revenue cross-sell to existing Industrial Precision Solutions customers.
FY2026 expected IPS toward $1.45-1.55B (+3-7%) on: (i) selected industrial cycle recovery; (ii) ARAG full-year contribution; (iii) selected precision agriculture market expansion (selected post-2024 European farm equipment cycle); (iv) selected adhesive dispensing recovery.
Medical & Fluid Solutions + Advanced Technology Solutions
Medical & Fluid Solutions ~$700M FY2025 (~25% of total) reflects: (i) selected medical device fluid components (post-2017 Vention Medical integration); (ii) selected interventional + selected diagnostic; (iii) selected post-2024 medical device cycle stability + selected continued aging demographic tailwind. Advanced Technology Solutions ~$700M (~25%) reflects: (i) selected electronics dispensing (post-2022 CyberOptics); (ii) selected test/inspection (selected semiconductor + selected electronics); (iii) selected post-2024 semiconductor capex recovery cycle.
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $2.59B | $2.63B | $2.69B | $2.6-2.8B | $2.7-2.9B |
| Industrial Precision | $1.45B | $1.39B | $1.41B | $1.4B | $1.45-1.55B |
| Medical & Fluid | $0.46B | $0.50B | $0.50B | $0.7B | $0.7-0.75B |
| Advanced Technology | $0.69B | $0.74B | $0.78B | $0.7B | $0.7-0.75B |
| Adj. Operating Margin | 31% | 32% | 31% | 30-32% | 30-33% |
| Adj. EPS | $9.83 | $10.20 | $9.51 | $8.50-10.00 | $9.00-10.50 |
| FCF | $560M | $620M | $580M | $500-650M | $550-700M |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $2.62 | $2.72-2.85 | $2.90-3.10 |
| Dividend Continuous Years | ~61 | ~62 | ~63 |
| Buybacks | $50M | $50-200M | $100-300M |
| Total Capital Return | $200M | $200-360M | $260-470M |
| Credit Rating | A2/A | A2/A | A2/A |
Market Evaluation
NDSN currently trades at ~22-28x earnings reflecting: (i) selected ~62-year continuous dividend track record (one of most prestigious in S&P 500); (ii) selected category-leading precision dispensing franchise; (iii) selected ~30%+ adj. operating margin; (iv) selected diversified end-market exposure; offset by (v) selected industrial cycle dependency; (vi) selected post-ARAG deleveraging.
Selected peer comparison: Graco (GGG ~22-25x P/E precision dispensing), Watts Water (WTS ~17-20x P/E water plumbing), Roper Technologies (ROP ~25-30x P/E diversified industrial software), Dover (DOV ~20-23x P/E diversified industrial). NDSN valuation reflects category-leading positioning with selected dividend aristocrat premium.
FY2026 catalysts: (i) industrial cycle recovery; (ii) ARAG integration; (iii) ~63-year dividend track; (iv) buyback resumption. Risks: (i) major industrial cycle reversal; (ii) ARAG integration impairment; (iii) competitive intensity from Graco; (iv) currency translation severe.
Industrial Cycle Recovery and Dividend Aristocrat Continuity
The FY2026 thesis hinges on Nordson's ability to capture industrial cycle recovery + integrate ARAG successfully + sustain ~63-year dividend track. Industrial Precision Solutions trajectory toward $1.45-1.55B FY2026 (+3-7%) signals selected industrial cycle recovery + ARAG full-year contribution + precision agriculture expansion.
Total revenue $2.7-2.9B FY2026 (+3-5%) + adj. EPS $9.00-10.50 (+5-10%) reflects selected operational leverage + selected buyback resumption. Capital return at $260-470M FY2026 maintaining ~63-year dividend track + selected modest buyback resumption post-ARAG deleveraging.
Material risks: (i) major industrial cycle reversal (revenue declines below FY2024); (ii) ARAG integration impairment; (iii) Graco competitive substitution severe; (iv) major dividend growth deceleration below 3% (would erode aristocrat trajectory).
FY2026-2027 base case: revenue $2.7-2.9B (+3-5%) + $2.8-3.0B (+3-5%); adj. EPS $9.00-10.50 + $9.50-11.00 (+5-7% growth); dividend $2.90-3.10 + $3.05-3.30 maintaining 63-64 consecutive year dividend track; capital return $260-470M + $300-500M. Selected category-leading precision dispensing franchise + selected longest NASDAQ dividend aristocrat track record + selected disciplined capital allocation support continued compounding through FY2027.